U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT06893796) titled 'Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females' on March 06.
Brief Summary: This is an open-label, Phase Ia clinical study to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of single dose of telpegfilgrastim injection in healthy premenopausal non-pregnant women. It plans to enroll 18 healthy premenopausal non-pregnant female.,). Participants will be enrolled sequentially according to their screening numbers in the following three dose groups:0.25mg, 0.5mg, and 1mg, with 6 participants in each dose group. Each participant will undergo a screen...